ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings Inc., today updated recent results of a study for its lead compound Homspera®. In combination with a DNA vaccine using Scancell’s patented ImmunoBody® technology, Homspera significantly improved the immune response of the vaccine in an animal model.
ImmuneRegen said it’s currently conducting follow-up studies to optimize Homspera’s efficacy in enhancing the next generation of Scancell’s cancer vaccines.
Scancell recently started a phase I clinical trial for SCIB1, its novel product in development for the treatment of melanoma centered on its ImmunoBody technology.
Scancell’s Immunobody technology is unique in that a different component of the engineered antibody leads to a significant enhancement of the immune response.
“We are pleased to see we can positively augment immune responses elicited by Scancell’s ImmunoBody vaccines,” Hal Siegel Ph.D., ImmuneRegen’s chief scientific officer stated in the press release. “Based on our previous demonstration of enhanced dendritic cell responses to TRP2-encoding DNA vaccine following Homspera exposure, Scancell’s ImmunoBody vaccine technology presents a very desirable developmental opportunity. We are very happy with our ongoing relationship and recognize that ongoing studies could potentially benefit both companies.”
Homspera was previously found to improve the efficacy of a melanoma cancer vaccine in mice; previous studies also demonstrated Homspera’s efficacy in enhancing immune responses to infectious disease vaccines. According to today’s press release, ImmuneRegen is working with academic and industry partners to develop applications for melanoma and infectious disease vaccines.
For more information visit: www.immuneregen.com
Let us hear your thoughts below:
